NCT06132126CompletedPhase 1
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 24 Jul 2024
Brief summary (registry, in English)
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- First submitted
- 10 Nov 2023
- Start date
- 17 Nov 2023
- Primary completion date
- 28 Jun 2024
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT06132126
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 66
- From 17 Nov 2023 to the primary completion date, 28 Jun 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have been treated with sulfonylurea, thiazolidinedione, alpha-glucosidase inhibitor, glucagon-like peptide-1 receptor agonist or Insulin within the previous 3 months
- Have received chronic systemic glucocorticoid therapy in the past 3 months
- Are currently enrolled in another clinical study trial involving medical research, or have participated within the last 30 days in a clinical study involving an investigational product.
Other
- Have proliferative retinopathy or maculopathy and/or severe neuropathy
Who the study is looking for
- Male and female participants who are overtly healthy as determined by medical evaluation (Part A)
- Participants with T2DM diagnosed greater than 1 year before enrollment (Part A and Part B)
- Have a body mass index within the range of 18.5 to less than or equal to (\<=) 32 kilograms per square meter (kg/m²) for healthy participants and 18.5 to 40 kg/m² for T2DM participants.
- Male or female participants of nonchildbearing potential
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CenExel ACT Coordinator of this site? Confirm its status | Anaheim | United States | Unknown status |
| Labcorp CRU Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Qps-Mra, Llc. Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.